StoxOnesource Specialty Pharma vs Vijaya Diagnostic Centre: share price & financials comparison
NSE: ONESOURCE vs VIJAYA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Onesource Specialty Pharma vs Vijaya Diagnostic Centre at a glance
Onesource Specialty Pharma (ONESOURCE) has a market capitalisation of ₹18,463 Cr, against ₹14,524 Cr for Vijaya Diagnostic Centre (VIJAYA). Over the past year Vijaya Diagnostic Centre has returned +37.5%, compared with -12.2% for Onesource Specialty Pharma. Vijaya Diagnostic Centre earns a higher return on equity (19.3% vs -0.0%). Onesource Specialty Pharma comes out ahead on valuation and growth. Vijaya Diagnostic Centre comes out ahead on size, profitability, momentum and technicals. Across the scored metrics below, Onesource Specialty Pharma leads on 4 and Vijaya Diagnostic Centre on 7. On StoxGud's 10-point checklist, Onesource Specialty Pharma scores 4/10 and Vijaya Diagnostic Centre scores 8/10.
| Metric | Onesource Specialty Pharma | Vijaya Diagnostic Centre |
|---|---|---|
| Size | ||
| Market cap | ₹18,463 Cr | ₹14,524 Cr |
| Revenue (latest FY) | ₹1,422 Cr | ₹814 Cr |
| Net profit (latest FY) | ₹-74 Cr | ₹173 Cr |
| Valuation | ||
| P/E | — | 71.3 |
| P/B | 3.12 | 13.74 |
| Dividend yield | — | 0.14% |
| Profitability | ||
| Return on equity | 0.0% | 19.3% |
| Net profit margin | -0.1% | 22.4% |
| Operating margin | 23.5% | 43.1% |
| Growth | ||
| Revenue growth (YoY) | +37.4% | +26.7% |
| Net profit growth (YoY) | +687.0% | +37.4% |
| Revenue CAGR (multi-year) | — | +15.2% |
| Financial health | ||
| Debt to equity | 0.25 | 0.00 |
| Momentum | ||
| 1-month return | +10.3% | +0.3% |
| 1-year return | -12.2% | +37.5% |
| 3-year CAGR | — | +31.3% |
| 5-year CAGR | — | +20.0% |
| Distance from 52W high | -13.8% | -10.2% |
| Technicals | ||
| RSI (14) | 82 | 54 |
| Price vs 200-day avg | +4.0% | +12.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Onesource Specialty Pharma | Vijaya Diagnostic Centre |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 4/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Onesource Specialty Pharma or Vijaya Diagnostic Centre?
Onesource Specialty Pharma has a market cap of ₹18,463 Cr and Vijaya Diagnostic Centre has a market cap of ₹14,524 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Onesource Specialty Pharma or Vijaya Diagnostic Centre?
Vijaya Diagnostic Centre did better: Onesource Specialty Pharma returned -12.2% and Vijaya Diagnostic Centre returned +37.5% over one year.
What is the difference between Onesource Specialty Pharma and Vijaya Diagnostic Centre?
Both are NSE-listed companies in Healthcare. Onesource Specialty Pharma is about 1.3 times the size of Vijaya Diagnostic Centre by market cap. In the latest financial year Onesource Specialty Pharma reported revenue of ₹1,422 Cr and Vijaya Diagnostic Centre ₹814 Cr. Operating margin is 23.5% for Onesource Specialty Pharma and 43.1% for Vijaya Diagnostic Centre. Debt to equity is 0.25 for Onesource Specialty Pharma and 0.00 for Vijaya Diagnostic Centre.
Which is better, Onesource Specialty Pharma or Vijaya Diagnostic Centre?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Onesource Specialty Pharma leads on 4 and Vijaya Diagnostic Centre on 7. Onesource Specialty Pharma is ahead on valuation and growth. Vijaya Diagnostic Centre is ahead on size, profitability, momentum and technicals. On StoxGud's rules-based checklist Onesource Specialty Pharma scores 4/10 and Vijaya Diagnostic Centre scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.